Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Update on immunotherapy in MDS

Stephen Nimer • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Antibodies CAR-T Checkpoint inhibitors

Stephen Nimer, MD, Sylvester Comprehensive Cancer Center and University of Miami, Miami, FL, discusses immunotherapy for myelodysplastic syndromes (MDS), including allogeneic stem cell transplantation and CAR T-cell therapy. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Stephen Nimer

0:53
How to improve transplant outcomes in MDS?
Stephen Nimer • 5 Mar 2020
1:02
Stephen Nimer: MDS highlights
Stephen Nimer • 5 Mar 2020
1:19
The promise of precision medicine in MDS
Stephen Nimer • 5 Mar 2020
1:01
Evolving role of next-generation sequencing in MDS
Stephen Nimer • 5 Mar 2020

Related Videos

2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals